Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Evotec AG    EVT   DE0005664809

EVOTEC AG (EVT)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about EVOTEC AG
10/12 EVOTEC : achieves first milestone in neurodegeneration alliance with Celgene
10/10 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/10 EVOTEC : Achieves first milestone in neurodegeneration alliance with celgene
10/02 EVOTEC : invests in Exscientia to advance AI-driven drug discovery
09/29 EVOTEC AG : Release according to Article 26a of the WpHG [the German Securities ..
09/28 EVOTEC : Invests in Exscientia to Advance AI-Driven Drug Discovery
09/28 EVOTEC : Invests in exscientia to advance ai-driven drug discovery
09/18 EVOTEC AG : Notification and public disclosure of transactions by persons
09/18 EVOTEC AG : Notification and public disclosure of transactions by persons
09/14 EVOTEC : and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto
09/14 EVOTEC : And mars innovation establish academic bridge 'lab150' in toronto
09/12 EVOTEC : European Investment Bank supports Evotec's Innovate strategy with EUR 7..
09/08 EVOTEC AG : Notification and public disclosure of transactions by persons
09/08 EVOTEC : European Investment Bank Supports Evotec's Innovate Strategy with EUR 7..
09/08 EVOTEC : European investment bank supports evotec's innovate strategy with eur 7..
More most relevant news
All news about EVOTEC AG
10/19 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/12 EVOTEC : achieves first milestone in neurodegeneration alliance with Celgene
10/10 EVOTEC : Achieves First Milestone in Neurodegeneration Alliance with Celgene
10/10 EVOTEC : Achieves first milestone in neurodegeneration alliance with celgene
10/02 EVOTEC : invests in Exscientia to advance AI-driven drug discovery
09/29 EVOTEC AG : Release according to Article 26a of the WpHG [the German Securities ..
09/28 EVOTEC : Invests in Exscientia to Advance AI-Driven Drug Discovery
09/28 EVOTEC : Invests in exscientia to advance ai-driven drug discovery
09/21 EVOTEC : and MaRS Innovation Establish Academic Bridge 'LAB150' in Toronto
09/18 EVOTEC AG : Notification and public disclosure of transactions by persons
More news
Sector news : Biotechnology & Medical Research - NEC
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval -- Update
10/18DJGILEAD SCIENCES : Cell-Therapy Drug Yescarta Gets FDA Approval
10/18DJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
10/17 Regeneron-Sanofi drug succeeds mid-stage study
10/17DJJOHNSON & JOHNSON : Outlook Buoyed by Drug Unit -- Update
10/17DJJOHNSON & JOHNSON : Raises Guidance on Earnings Beat
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
10:22a Evotec short pitch at Robin Hood conference; shares fall 4%
09/28 Evotec invests in Exscientia to advance AI-driven drug discovery
08/10 Evotec's (EVOTF) CEO Werner Lanthaler on Q2 2017 Results - Earnings Call Tran..
08/10 Evotec AG 2017 Q2 - Results - Earnings Call Slides
08/10 Evotec AG reports Q2 results
07/31 Evotec AG (EVTCY) to Acquire Aptuit - M&A Slideshow
Latest Tweets
04:22pEvotec short pitch at Robin Hood conference; shares fall 4%
1
10/19Forge Therapeutics, Evotec launch platform to discover metalloenzyme inhibito.. 
10/19Forge Therapeutics, Evotec launch platform to discover metalloenzyme inhibito..
1
10/12Evotec AG $EVTCY Upgraded at Zacks Investment Research  
10/12Evotec AG $EVTCY Rating Lowered to Hold at Zacks Investment Research  
More tweets
Qtime:26
Financials (€)
Sales 2017 232 M
EBIT 2017 40,9 M
Net income 2017 26,8 M
Debt 2017 10,9 M
Yield 2017 -
P/E ratio 2017 114,31
P/E ratio 2018 79,13
EV / Sales 2017 13,2x
EV / Sales 2018 9,70x
Capitalization 3 035 M
Chart EVOTEC AG
Duration : Period :
Evotec AG Technical Analysis Chart | EVT | DE0005664809 | 4-Traders
Technical analysis trends EVOTEC AG
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 13,2 €
Spread / Average Target -36%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Mario Polywka Chief Operating Officer
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC AG192.93%3 793
INCYTE CORPORATION13.96%24 254
QUINTILES IMS HOLDINGS INC33.89%21 711
CELLTRION, INC.--.--%20 802
LONZA GROUP59.15%19 730
ALNYLAM PHARMACEUTICALS, INC.208.84%10 783